Current and future microbicide approaches aimed at preventing HIV infection in women

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 2, 2012, Pages 167-183

  Pozzetto, Bruno ^a   Delézay, Olivier ^a   Brunon Gagneux, Amandine ^a   Hamzeh Cognasse, Hind ^a   Lucht, Frédéric ^a   Bourlet, Thomas ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

Author keywords

antiretroviral; female genital tract; HIV; microbicide; pre exposure prophylaxis; prevention; sexually transmitted diseases; woman

Indexed keywords

AMPHORA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BUFFER GEL; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; CYCLODEXTRIN; DAPIVIRINE; DODECYL SULFATE SODIUM; EMTRICITABINE; GLYCEROL MONOLAURATE; GLYCOPROTEIN GP 120; GOLD NANOPARTICLE; INTEGRASE INHIBITOR; MICROBICIDE; MIV 150; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NONOXINOL 9; PLACEBO; PRO 2000; PROTEINASE INHIBITOR; RC 101; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; SILVER NANOPARTICLE; SPI 7013; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USHERSHELL;

CD4+ T LYMPHOCYTE; CREAM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SCREENING; EX VIVO STUDY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FEMALE; FEMALE GENITAL TRACT INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; IN VITRO STUDY; INFECTION PREVENTION; MICROENVIRONMENT; RECEPTOR BINDING; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA RING; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS LOAD; VIRUS TRANSMISSION; WOMEN'S HEALTH;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CONTRACEPTION; CONTRACEPTIVE DEVICES, FEMALE; DEVELOPING COUNTRIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MUCOUS MEMBRANE; RECEPTORS, HIV; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VIRUS INTERNALIZATION;

EID: 84857577385     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.173     Document Type: Review

References (116)

1. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam. Plan. Perspect. 31, 272-279 (1999).
2. Granich R, Crowley S, Vitoria M et al. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr. Opin. HIV AIDS 5, 298-304 (2010).
3. Mepham SO, Bland RM, Newell ML. Prevention of mother-to-child transmission of HIV in resource-rich and -poor settings. BJOG 118, 202-218 (2011).
4. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2(11), e298 (2005).
5. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643-656 (2007).
6. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657-666 (2007).
7. Dumond JB, Yeh RF, Patterson KB et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS 21, 1899-1907 (2007).
8. Chirenje ZM, Marrazzo J, Parikh UM. Antiretroviral-based HIV prevention strategies for women. Expert Rev. Anti Infect. Ther. 8(10), 1177-1186 (2010).
9. De Clercq E. Pre-exposure chemoprophylaxis of HIV infection: quo vadis? Biochem. Pharmacol. doi:10.1016/j. bcp.2011.10.016 (2011) (Epub ahead of print).
10. Cohen J. Is an effective HIV vaccine feasible? Science 309, 99 (2005).
11. Kaiser J. AIDS research. Review of vaccine failure prompts a return to basics. Science 320, 30-31 (2008).
12. Gray RH, Li X, Kigozi G et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366, 1182-1188 (2005).
13. Dinh FH, Goya A, Jackson D et al. HIV acquired during pregnancy: finding from the national prevention of mother-to-child transmission (PMTCT) survey in South Africa (2010). Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
14. Grant RM, Hamer D, Hope T et al. Whither or wither microbicides? Science 321, 532-534 (2008).
15. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
16. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1, 25-34 (2003).
17. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8, 447-457 (2008).
18. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6, 20-28 (2009).
19. Khanna KV, Whaley KJ, Zeitlin L et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109, 205-211 (2002).
20. Kaizu M, Weiler AM, Weisgrau KL et al. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J. Infect. Dis. 194, 912-916 (2006).
21. + T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J. Virol. 76, 9868-9876 (2002).
22. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3, 42-47 (1997).
23. Patterson BK, Landay A, Andersson J et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am. J. Pathol. 153, 481-490 (1998).
24. Yeaman GR, Asin S, Weldon S et al. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type 1. Immunology 113, 524-533 (2004).
25. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137, 433-444 (2009).
26. Yahi N, Baghdiguian S, Moreau H, Fantini J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J. Virol. 66, 4848-4854 (1992).
27. Fantini J, Yahi N, Delezay O, Gonzalez-Scarano F. GalCer, CD26 and HIV infection of intestinal epithelial cells. AIDS 8, 1347-1348 (1994).
28. Alfsen A, Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277, 25649-25659 (2002).
29. Nguyen DG, Hildreth JEK. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 33, 483-493 (2003).
30. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol. Immunol. 42, 145-152 (2005).
31. Turville SG, Cameron PU, Handley A et al. Diversity of receptors binding HIV on dendritic cell subsets. Nat. Immunol. 3, 975-983 (2002).
32. Vidricaire G, Gauthier S, Tremblay MJ. HIV-1 infection of trophoblasts is independent of gp120/CD4 interactions but relies on heparan sulfate proteoglycans. J. Infect. Dis. 195, 1461-1471 (2007).
33. De Witte L, Bobardt M, Chatterji U et al. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc. Natl Acad. Sci. USA 104, 19464-19469 (2007).
34. Stoddard E, Cannon G, Ni H et al. gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J. Immunol. 179, 3126-3132 (2007).
35. Cannon G, Yi Y, Ni H et al. HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection. J. Immunol. 181, 2065-2070 (2008).
36. Arthos J, Cicala C, Martinelli E et al. HIV-1 envelope protein binds to and signals through integrin a4b7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309 (2008).
37. Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am. J. Reprod. Immunol. 65, 325-333 (2011).
38. Hladik F, Doncel GF. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res. 88, S3-S9 (2010).
39. Tevi-Bénissan C, Bélec L, Lévy M et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin. Diagn. Lab. Immunol. 4, 367-374 (1997).
40. Kim KA, Yolamanova M, Zirafi O et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 7, 55 (2010).
41. Berlier W, Cremel M, Hamzeh H et al. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum. Reprod. 21, 1135-1142 (2006).
42. Mburu N, Obiero JA, Waititu K et al. Safety studies of a recently developed microbicidal contraceptive gel (UniPron) in female baboons (Papio anubis). Afr. J. Reprod. Health 13, 95-104 (2009).
43. Du Toit LC, Pillay V, Choonara YE. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv. Drug Deliv. Rev. 62, 532-546 (2010).
44. Pusch O, Boden D, Hannify S et al. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J. Acquired Immune Defic. Syndromes 40, 512-520 (2005).
45. Wayengera M. Why bacteria derived R-M nucleic enzymatic peptides are likely efficient therapeutic molecules for use in the design and development of novel HIV inhibitory strategies. Afr. J. Biotechnol. 7, 1791-1796 (2008).
46. Tao J, Hu Q, Yang J et al. In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. Antiviral Res. 75, 227-233 (2007).
47. Cheng G, Montero A, Gastaminza P et al. A virocidal amphipathic {a}-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 105, 3088-3093 (2008).
48. Bobardt MD, Cheng G, de Witte L et al. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl Acad. Sci. USA 105, 5525-5530 (2008).
49. Botos I, Wlodawer A. Cyanovirin N: a sugar-binding antiviral protein with a new twist. Cell Mol. Life Sci. 60, 277-287 (2003).
50. O'Keefe BR, Vojdani F, Buffa V et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl Acad. Sci. USA 106, 6099-6104 (2009).
51. De Parseval A, Bobardt MD, Chatterji A et al. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulphated motifs. J. Biol. Chem. 280, 39493-39504 (2005).
52. Penberthy WT, Chari S, Cole AL, Cole AM. Retrocyclins and their activity against HIV-1. Cell Mol. Life Sci. 68, 2231-2242 (2011).
53. Gallo SA, Wang W, Rawat SS et al. q-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J. Biol. Chem. 281, 18787-18792 (2006).
54. Sassi AB, Cost MR, Cole AL et al. Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob. Agents Chemother. 55, 2282-2289 (2011).
55. Welch BD, Francis JN, Redman JS et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84, 11235-11244 (2010).
56. Burkly LC, Olson D, Shapiro R et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149, 1779-1787 (1992).
57. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J. Allergy Clin. Immunol. 118, 1369-1374 (2006).
58. Vermeire K, Brouwers J, Van Herrewege Y et al. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr. HIV Res. 6, 246-256 (2008).
59. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob. Agents Chemother. 54, 2753-2766 (2010).
60. D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 57, 411-423 (2006).
61. Dobard C, Sharma S, Parikh U et al. High protection against vaginal infection in macaques by PEP with gel containing RAL. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-3 March 2011.
62. Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett. 15, 3615-3618 (2005).
63. Li Q, Estes JD, Schlievert PM et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038 (2009).
64. Talwar GP, Raghuvanshi P, Mishra R et al. Polyherbal formulations with wide spectrum antimicrobial activity against reproductive tract infections and sexually transmitted pathogens. Am. J. Reprod. Immunol. 43, 144-151 (2000).
65. Haraguchi Y, Sakurai H, Hussain S, Anner BM, Hoshino H. Inhibition of HIV-1 infection by zinc group metal compounds. Antiviral Res. 43, 123-133 (1999).
66. Saïdi H, Jenabian MA, Gombert B, Charpentier C, Mannarini A, Bélec L. Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5-and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity. AIDS Res. Ther. 5, 10 (2008).
67. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 11, 78-87 (2009).
68. Buckheit RW Jr, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 85, 142-158 (2010).
69. Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res. 88, S19-S29 (2010).
70. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 88, S30-S39 (2010).
71. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res. 88, S55-S66 (2010).
72. Tien D, Schnaare RL, Kang F et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res. Hum. Retroviruses 21, 845-853 (2005).
73. Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 6, e15835 (2011).
74. Lard-Whiteford SL, Matecka D, O'Rear JJ et al. Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J. Acquired Immune Defic. Syndromes 36, 541-552 (2004).
75. Cummins JE Jr, Guarner J, Flowers L et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 51, 1770-1779 (2007).
76. Doncel GF, Clark MR. Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res. 88, S10-S18 (2010).
77. Gali Y, Ariën KK, Praet M et al. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J. Virol. Methods 165, 186-197 (2010).
78. Gali Y, Delezay O, Brouwers J et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob. Agents Chemother. 54, 5105-5114 (2010).
79. Jenabian MA, Saïdi H, Charpentier C et al. Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Res. Ther. 7, 16 (2010).
80. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 85-93 (1969).
81. Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268, 477-482 (1992).
82. Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339, 504-510 (1998).
83. Van Damme L, Ramjee G, Alary M et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360, 971-977 (2002).
84. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo: the story of nonoxynol 9. J. Acquired Immune Defic. Syndromes 39, 1-8 (2005).
85. Beer BE, Doncel GF, Krebs FC et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob. Agents Chemother. 50, 713-723 (2006).
86. Rovinsky JJ. Clinical effectiveness of a contraceptive cream. Obstet. Gynecol. 23, 125-131 (1964).
87. Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3, e1474 (2008).
88. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359, 463-472 (2008).
89. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1977-1987 (2008).
90. Karim SA, Coletti A, Richardson B et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada, 8-11 February 2009.
91. Tao W, Richards C, Hamer D. Enhancement of HIV infection by cellulose sulphate. AIDS Res. Hum. Retroviruses 24, 925-929 (2008).
92. Patel S, Hazrati E, Cheshenko N et al. Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J. Infect. Dis. 196, 1394-1402 (2007).
93. Omar RF, Bergeron MG. The future of microbicides. Int. J. Infect. Dis. 15, e656-e660 (2011).
94. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res. 71, 343-350 (2006).
95. Friend DR, Doncel GF. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 88, S47-S54 (2010).
96. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438, 99-102 (2005).
97. Ballagh SA, Brache V, Mauck C et al. A Phase 1 study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception 77, 130-137 (2008).
98. Schwartz JL, Ballagh SA, Creinin MD et al. SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception 78, 237-244 (2008).
99. Thigpen MC, Kebaabetswe PM, Smith DK. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Presented at: 6th IAS Conference on HIV Pathogenesis,Ttreatment and Prevention. Rome, Italy, 17-20 July 2011.
100. Baeten J. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the partners PrEP study. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011.
101. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat. Biotechnol. 25, 1444-1454 (2007).
102. Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J. Acquired Immune Defic. Syndromes 58(2), 207-210 (2011).
103. Williams DL, Newman DR, Ballagh SA et al. Phase 1 safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex. Transm. Dis. 34, 977-984 (2007).
104. Low-Beer N, Gabe R, McCormack S, Kitchen VS, Lacey CJ, Nunn AJ. Dextrin sulphate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J. Acquired Immune Defic. Syndromes 31, 391-398 (2002).
105. Herold BC, Scordi-Bello I, Cheshenko N et al. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J. Virol. 76, 11236-11244 (2002).
106. 2+ signaling dysregulation. J. Androl. 27, 568-577 (2006).
107. Chang TL, Teleshova N, Rapista A et al. SAMMA, a mandelic acid condensation polymer, inhibits dendritic cell-mediated HIV transmission. FEBS Lett. 581, 4596-4602 (2007).
108. Passic SR, Ferguson ML, Catalone BJ, Yedery RD. Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed. Pharmacother. 64, 723-732 (2010).
109. Reddy KV, Aranha C, Gupta SM et al. Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies. Reproduction 128, 117-126 (2004).
110. McCarthy TD, Karellas P, Henderson SA et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312-318 (2005).
111. Guo Q, Ho HT, Dicker I et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77, 10528-10536 (2003).
112. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348, 2228-2238 (2003).
113. Van Herrewege Y, Michiels J, Van Roey J et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48, 337-339 (2004).
114. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J. Antimicrob. Chemother. 56, 954-956 (2005).
115. Van Herrewege Y, Vanham G, Michiels J et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob. Agents Chemother. 48, 3684-3689 (2004).
116. Mahalingam A, Simmons AP, Ugaonkar SR et al. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob. Agents Chemother. 55, 1650-1660 (2011).